Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4A | O75164 | 8/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | TET2 | Q6N021 | 1/20 | 1.00 |
| ▸ | DOHH | Q9BU89 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.92 |
| ▸ | LMNA | P02545 | 1/20 | 0.92 |
| ▸ | GAA | P10253 | 1/20 | 0.92 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.92 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.46 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 7/20 | 0.40 |
| ▸ | CASP2 | P42575 | 1/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.37 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.37 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.37 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17109729 | 1.00 | KDM4A (1.00) | KDM4AHIF1ATET2DOHHKDM4E | |
| SCHEMBL13367139 | 1.00 | KDM4A (1.00) | KDM4AHIF1ATET2DOHHKDM4E | |
| SCHEMBL21051754 | 1.00 | KDM4A (1.00) | KDM4AHIF1ATET2DOHHKDM4E | |
| Deferoxamine SCHEMBL10498260 | 1.00 | KDM4A (1.00) | KDM4AHIF1ATET2DOHHKDM4E | |
| Deferoxamine SCHEMBL34571 | 1.00 | KDM4A (1.00) | KDM4AHIF1ATET2DOHHKDM4E | |
| SCHEMBL19040665 | 1.00 | KDM4A (1.00) | KDM4AHIF1ATET2DOHHKDM4E | |
| SCHEMBL26511991 | 1.00 | KDM4A (1.00) | KDM4AHIF1ATET2DOHHKDM4E | |
| Deferoxamine SCHEMBL20658962 | 0.99 | KDM4A (0.97) | KDM4AHIF1ATET2DOHHKDM4E | |
| Deferoxamine SCHEMBL21049242 | 0.99 | KDM4A (0.97) | KDM4AHIF1ATET2DOHHKDM4E | |
| Deferoxamine SCHEMBL20658960 | 0.99 | KDM4A (0.97) | KDM4AHIF1ATET2DOHHKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025088147-A1 | THERANOSTIC PSMA-TARGETING LIGANDS FOR THE DIAGNOSIS AND TREATMENT OF PSMA-EXPRESSING CANCERS AND THEIR SOLID PHASE SYNTHESIS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2025-05-01 | — | — | WO | claimed |
| US-20230406847-A1 | LIGANDS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) CONTAINING HETEROAROMATIC LINKER BUILDING BLOCKS | ABX ADVANCED BIOCHEMICAL COMPOUNDS GMBH (DE) | 2023-12-21 | — | — | US | claimed |
| EP-4244216-A1 | LIGANDS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) CONTAINING HETEROAROMATIC LINKER BUILDING BLOCKS | ABX Advanced Biochemical Compounds GmbH (DE) | 2023-09-20 | — | — | EP | claimed |
| WO-2022101352-A1 | LIGANDS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) CONTAINING HETEROAROMATIC LINKER BUILDING BLOCKS | ABX ADVANCED BIOCHEMICAL COMPOUNDS GMBH (DE) | 2022-05-19 | — | — | WO | claimed |
| EP-4577578-A1 | DLL3 BINDING MOLECULES AND USES THEREOF | Abdera Therapeutics Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| EP-4577526-A1 | VHH ANTIBODY CONJUGATES | Abdera Therapeutics Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| EP-4577250-A1 | MULTIVALENT IMMUNOCONJUGATES FOR TARGETED RADIOISOTOPE THERAPY | Abdera Therapeutics Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| WO-2025088147-A1 | THERANOSTIC PSMA-TARGETING LIGANDS FOR THE DIAGNOSIS AND TREATMENT OF PSMA-EXPRESSING CANCERS AND THEIR SOLID PHASE SYNTHESIS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2025-05-01 | — | — | WO | disclosed |
| US-20250127938-A1 | THERAGNOSTIC FOLATE CONJUGATES | MERCK PATENT GMBH (DE) | 2025-04-24 | — | — | US | disclosed |
| US-20250108138-A1 | THERAGNOSTIC FOLATE CONJUGATES | MERCK PATENT GMBH (DE) | 2025-04-03 | — | — | US | disclosed |
| EP-4472677-A1 | THERAGNOSTIC FOLATE CONJUGATES | Merck Patent GmbH (DE) | 2024-12-11 | — | — | EP | disclosed |
| EP-4472676-A1 | THERAGNOSTIC FOLATE CONJUGATES | Merck Patent GmbH (DE) | 2024-12-11 | — | — | EP | disclosed |
| EP-3131585-B1 | MULTIDENTATE BIFUNCTIONAL CHELATING AGENTS FOR RADIONUCLIDE COMPLEXATION IN DIAGNOSTICS AND THERAPY | UNIV ZUERICH (CH) | 2020-07-15 | — | — | EP | disclosed |
| EP-3131585-B1 | MULTIDENTATE BIFUNCTIONAL CHELATING AGENTS FOR RADIONUCLIDE COMPLEXATION IN DIAGNOSTICS AND THERAPY | UNIV ZUERICH (CH) | 2020-07-15 | — | — | EP | disclosed |
| US-20170106106-A1 | MULTIDENTATE BIFUNCTIONAL CHELATING AGENTS FOR RADIONUCLIDE COMPLEXATION IN DIAGNOSTICS AND THERAPY | UNIVERSITAT ZURICH (CH) | 2017-04-20 | — | — | US | disclosed |
| US-20170106106-A1 | MULTIDENTATE BIFUNCTIONAL CHELATING AGENTS FOR RADIONUCLIDE COMPLEXATION IN DIAGNOSTICS AND THERAPY | UNIVERSITAT ZURICH (CH) | 2017-04-20 | — | — | US | disclosed |
| US-20170106106-A1 | MULTIDENTATE BIFUNCTIONAL CHELATING AGENTS FOR RADIONUCLIDE COMPLEXATION IN DIAGNOSTICS AND THERAPY | UNIVERSITAT ZURICH (CH) | 2017-04-20 | — | — | US | disclosed |
| EP-3131585-A1 | MULTIDENTATE BIFUNCTIONAL CHELATING AGENTS FOR RADIONUCLIDE COMPLEXATION IN DIAGNOSTICS AND THERAPY | Universität Zürich (CH) | 2017-02-22 | — | — | EP | disclosed |
| WO-2015140212-A1 | MULTIDENTATE BIFUNCTIONAL CHELATING AGENTS FOR RADIONUCLIDE COMPLEXATION IN DIAGNOSTICS AND THERAPY | Universität Zürich (CH) | 2015-09-24 | — | — | WO | disclosed |
| WO-2015140212-A1 | MULTIDENTATE BIFUNCTIONAL CHELATING AGENTS FOR RADIONUCLIDE COMPLEXATION IN DIAGNOSTICS AND THERAPY | Universität Zürich (CH) | 2015-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170106106-A1 | MULTIDENTATE BIFUNCTIONAL CHELATING AGENTS FOR RADIONUCLIDE COMPLEXATION IN DIAGNOSTICS AND THERAPY | AOC1, XDH, FOLR1 | KDM4A 3400/4885HIF1A 1613/4885TET2 4608/4885 |
| US-20230406847-A1 | LIGANDS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) CONTAINING HETEROAROMATIC LINKER BUILDING BLOCKS | KLK3, FOLH1, BPHL | KDM4A 1803/4885HIF1A 1645/4885TET2 4858/4885 |
| US-20250108138-A1 | THERAGNOSTIC FOLATE CONJUGATES | FOLR1, MTHFD1, MTHFD2 | KDM4A 2724/4885HIF1A 2958/4885TET2 361/4885 |
| US-20250127938-A1 | THERAGNOSTIC FOLATE CONJUGATES | FOLR1, FOLR2, DHFR | KDM4A 2949/4885HIF1A 4050/4885TET2 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.